,,it was interesting to hear back during the AGM that those on 208 wanted to remain on 208. Who pays for such if particpiants did remain on this drug. Did they stay on 208? Would the trial schedule be maintained with the same clinics administrating?,,,It must be assumed if any did remain on the trial dosing schedule they would still become part of the data collected and if so it must be assumed there is a cost involved. Just thinking.